‘Solve all diseases,’ you say?
TL;DR
At the end of his Google I/O keynote, DeepMind CEO Demis Hassabis declared that Google wants to 'reimagine the drug discovery process with the goal of one day solving all disease. ' The statement landed deadpan amid the usual product show. Critics see classic Silicon Valley moonshot rhetoric, while others point to AlphaFold and Isomorphic Labs already reshaping the pharma pipeline. The question: does AI actually accelerate drug discovery, or is the marketing outpacing the science?
Nauti's Take
Real opportunity: AlphaFold and Isomorphic Labs prove AI is genuinely speeding up drug discovery — protein folding and compound screening run noticeably faster than two years ago. The caveat: 'solving all disease' is classic moonshot rhetoric that inflates expectations and distracts from clinical reality.
Practical read: pharma pros and investors should separate research progress from PR — the tools are strong, the promise stays a headline.
Summary
At the end of his Google I/O keynote, DeepMind CEO Demis Hassabis declared that Google wants to 'reimagine the drug discovery process with the goal of one day solving all disease. ' The statement landed deadpan amid the usual product show.
Critics see classic Silicon Valley moonshot rhetoric, while others point to AlphaFold and Isomorphic Labs already reshaping the pharma pipeline. The question: does AI actually accelerate drug discovery, or is the marketing outpacing the science?
Sources